title: Benefit-risk analysis of adalimumab versus methotrexate and placebo in the treatment of moderate to severe psoriasis: comparison of adverse event-free response days in the CHAMPION trial.
authors.affiliation: Dermatologikum Hamburg, Hamburg, Germany. reich@dermatologikum.de
authors.forename: Kristian
authors.initials: K
authors.lastname: Reich
authors.forename: James
authors.initials: J
authors.lastname: Signorovitch
authors.forename: Karthik
authors.initials: K
authors.lastname: Ramakrishnan
authors.forename: Andrew P
authors.initials: AP
authors.lastname: Yu
authors.forename: Eric Q
authors.initials: EQ
authors.lastname: Wu
authors.forename: Shiraz R
authors.initials: SR
authors.lastname: Gupta
authors.forename: Yanjun
authors.initials: Y
authors.lastname: Bao
authors.forename: Parvez M
authors.initials: PM
authors.lastname: Mulani